Gossamer Bio, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GOSS research report →
Companywww.gossamerbio.com
Gossamer Bio, Inc. , a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis.
- CEO
- Faheem Hasnain
- IPO
- 2019
- Employees
- 144
- HQ
- San Diego, CA, US
Price Chart
Valuation
- Market Cap
- $50.34M
- P/E
- -0.28
- P/S
- 0.91
- P/B
- -0.31
- EV/EBITDA
- -1.25
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 99.58%
- Op Margin
- -321.92%
- Net Margin
- -324.82%
- ROE
- 174.85%
- ROIC
- -243.62%
Growth & Income
- Revenue
- $48.47M · -57.74%
- Net Income
- $-170,370,000 · -201.39%
- EPS
- $-0.75 · -200.00%
- Op Income
- $-163,253,000
- FCF YoY
- -4840.74%
Performance & Tape
- 52W High
- $3.87
- 52W Low
- $0.16
- 50D MA
- $0.38
- 200D MA
- $1.97
- Beta
- 2.15
- Avg Volume
- 17.18M
Get TickerSpark's AI analysis on GOSS
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 19, 26 | Aranda Richard | other | 572,000 |
| Mar 19, 26 | Aranda Richard | other | 562,500 |
| Mar 19, 26 | Aranda Richard | other | 487,500 |
| Mar 19, 26 | Aranda Richard | other | 162,500 |
| Mar 19, 26 | Aranda Richard | other | 157,500 |
| Mar 19, 26 | Aranda Richard | other | 126,667 |
| Mar 19, 26 | Aranda Richard | other | 40,000 |
| Mar 19, 26 | Aranda Richard | other | 30,000 |
| Mar 19, 26 | Aranda Richard | other | 22,784 |
| Mar 19, 26 | Aranda Richard | other | 20,000 |
Our GOSS Coverage
We haven't published any research on GOSS yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate GOSS Report →